Carregant...
Panobinostat and Multiple Myeloma in 2018
FDA and EMA approval of panobinostat offers an additional therapeutic option for multiple myeloma; however, adoption of panobinostat has been limited by its adverse event profile. Trials are ongoing to optimize the dosing of panobinostat and to identify its best partners, in order to fully realize t...
Guardat en:
| Publicat a: | Oncologist |
|---|---|
| Autors principals: | , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
AlphaMed Press
2018
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5947458/ https://ncbi.nlm.nih.gov/pubmed/29445026 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2017-0644 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|